RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Keros Therapeutics - Stock

Keros Therapeutics ROCE 2024

Keros Therapeutics ROCE

-0.51

Keros Therapeutics Dividend yield

Ticker

KROS

ISIN

US4923271013

WKN

A2P2YF

In 2024, Keros Therapeutics's return on capital employed (ROCE) was -0.51, a 23.62% increase from the -0.41 ROCE in the previous year.

Keros Therapeutics Aktienanalyse

What does Keros Therapeutics do?

Keros Therapeutics Inc is a biopharmaceutical company that was founded in 2015 by five biotechnology industry experts. The company is based in Lexington, Massachusetts. Keros is an emerging company that focuses on developing innovative therapies for severe diseases resulting from genetic defects. The business model of Keros Therapeutics Inc is to expand its pipeline of innovative therapies through the research, development, and commercialization of drugs that have highly specific mechanisms of action. Keros' business model aims to develop new and differentiated therapies that focus on modulating biological signals and pathways to improve the treatment of serious diseases. Keros Therapeutics Inc has several divisions that focus on different areas of biotechnology. One division of Keros specializes in the development of RNA-modulating therapies for diseases with genetic defects. These therapies target the modulation of RNA splicing processes to influence the causal factor of severe diseases. Another division of Keros focuses on the development of drugs that target the Wnt signaling pathway, a complex protein signaling network that plays an important role in many processes in the body. These Wnt-related drugs target various disease areas such as cancer and fibrosis to improve the treatment of these conditions. The company is currently in the clinical phase and has brought several products to market in various stages of research. One of Keros' key drug candidates is KER-012, a medication for the treatment of Alpha-1 antitrypsin deficiency, a rare and severe disease that often leads to lung and liver conditions. KER-012 aims to develop more effective treatment options for patients by specifically influencing an RNA splicing mechanism in the cells that is associated with the disease. Another drug candidate from Keros is KER-047, a medication for the treatment of Neurofibromatosis type 1, a rare condition that causes tumors in the nervous system. It targets the Wnt signaling pathway to restore control over tumor proliferation and enlargement. Keros has also established partnerships with other biotechnology companies and academic institutions to expand its research and development capabilities and diversify its pipeline. One notable agreement is the collaboration with Arbutus Biopharma to develop RNA modulators for cardiovascular diseases. Overall, Keros Therapeutics Inc aims to develop innovative and effective therapies for a variety of diseases by focusing on biology and signaling pathways that are responsible for disease progression. With a solid therapy pipeline and an experienced group of biotechnology experts, Keros could soon become a leading company in the biopharmaceutical industry. Keros Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Keros Therapeutics's Return on Capital Employed (ROCE)

Keros Therapeutics's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Keros Therapeutics's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Keros Therapeutics's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Keros Therapeutics’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Keros Therapeutics Stock

What is the ROCE (Return on Capital Employed) of Keros Therapeutics this year?

The ROCE of Keros Therapeutics is -0.51 undefined this year.

How has the ROCE (Return on Capital Employed) of Keros Therapeutics developed compared to the previous year?

The ROCE of Keros Therapeutics has increased by 23.62% increased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Keros Therapeutics?

A high Return on Capital Employed (ROCE) indicates that Keros Therapeutics has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Keros Therapeutics?

A low ROCE (Return on Capital Employed) can indicate that Keros Therapeutics has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Keros Therapeutics impact the company?

An increase in the ROCE of Keros Therapeutics can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Keros Therapeutics affect the company?

A decrease in ROCE of Keros Therapeutics can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Keros Therapeutics?

Some factors that can affect Keros Therapeutics's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Keros Therapeutics so important for investors?

The ROCE of Keros Therapeutics is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Keros Therapeutics take to improve the ROCE?

To improve the ROCE, Keros Therapeutics can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Keros Therapeutics pay?

Over the past 12 months, Keros Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Keros Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Keros Therapeutics?

The current dividend yield of Keros Therapeutics is .

When does Keros Therapeutics pay dividends?

Keros Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Keros Therapeutics?

Keros Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Keros Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Keros Therapeutics located?

Keros Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Keros Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Keros Therapeutics from 6/7/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/7/2024.

When did Keros Therapeutics pay the last dividend?

The last dividend was paid out on 6/7/2024.

What was the dividend of Keros Therapeutics in the year 2023?

In the year 2023, Keros Therapeutics distributed 0 USD as dividends.

In which currency does Keros Therapeutics pay out the dividend?

The dividends of Keros Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Keros Therapeutics

Our stock analysis for Keros Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Keros Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.